<DOC>
	<DOC>NCT01923545</DOC>
	<brief_summary>This study is to examine which dose of DA-3031(PEG-G-CSF) has similar efficacy and safety compared to daily G-CSF in chemotherapy-induced neutropenia.</brief_summary>
	<brief_title>Phase II Study of DA-3031(PEG-G-CSF) in Chemotherapy-induced Neutropenia</brief_title>
	<detailed_description>Eligible subjects are randomly assigned to receive once-per-cycle DA-3031(PEG-G-CSF) or daily G-CSF(up to 10 days). This study is conducted for 1 cycles of chemotherapy.</detailed_description>
	<mesh_term>Neutropenia</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>1. Diagnosis of stage II or III breast cancer 2. Age : ≥18, ≤70 3. TAC regimen as adjuvant therapy 4. ANC≥1,500/mm3, Platelet≥100,000/mm3, ECOG : 0 or 1 5. Creatinine &lt; 1.5 x ULN 6. Total bilirubin/AST/ALT &lt; 1.5 x ULN, ALP &lt; 2.5 x ULN 7. Have given a written, informed consent 1. Received any other investigational drugs within 30 days of informed consent date 2. Received systemic antibiotics within 72 hours of chemotherapy into this study or Radiation therapy within 4 weeks of informed consent date 3. Infective symptom before chemotherapy into this study 4. Pregnant or lactating women 5. Prior bone marrow or stem cell transplantation 6. Other malignancy history within 5 years 7. HIV positive 8. Prior exposure to pegfilgrastim or filgrastim or other colonystimulating factors within 6 weeks of informed consent date 9. Prior chemotherapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>PEG-G-CSF</keyword>
</DOC>